Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 795

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 795
---
 options

There were no changes in stock options during the three months ended September 30, 2024.

The following table summarizes stock options outstanding and exercisable under all plans at September 30, 2024:

|                    | Exercise price$ |     | NumberOutstanding atSeptember 30, 2024(in thousands) |     |     | Weightedaverage remainingcontractual life(years) |     |     | Numberexercisable atSeptember 30, 2024(in thousands) |
|:-------------------|:----------------|:----|-----------------------------------------------------:|:----|:----|-------------------------------------------------:|:----|:----|-----------------------------------------------------:|
| 162.93             |                 |     |                                                    2 |     |     |                                             8.92 |     |     |                                                    1 |
| 307.65             |                 |     |                                                    1 |     |     |                                             7.84 |     |     |                                                    1 |
| 1,067.50to1,680.00 |                 |     |                                                    2 |     |     |                                             7.36 |     |     |                                                    2 |
| 2,170.00to2,397.50 |                 |     |                                                    1 |     |     |                                             2.43 |     |     |                                                    — |
|                    |                 |     |                                                    6 |     |     |                                                  |     |     |                                                    4 |

The Company has recognized the following amounts as stock option expense for the periods noted (in thousands):

|                            |     | Three months endedSeptember 30, |    |     |       |     |
|                            |     |                           2024$ |    |     | 2023$ |     |
| Research and development   |     |                                 | 37 |     |       |  69 |
| General and administrative |     |                                 | 61 |     |       |  91 |
|                            |     |                                 | 98 |     |       | 160 |

<div align='center'>F-42</div>

All of the stock option expense for the periods ended September 30, 2024, and 2023, has been recognized as additional paid in capital. The aggregate intrinsic value of stock options outstanding as well as stock options exercisable was nil as of September 30, 2024, and 2023, respectively. As of September 30,